MULTICENTER STUDY
Add like
Add dislike
Add to saved papers

Visual experiences during vitreous surgery under regional anesthesia: a multicenter study.

PURPOSE: To investigate patients' subjective intraoperative visual experiences during vitreous surgery performed under regional anesthesia, to ascertain if patients were frightened by their visual experiences, and to determine the risk factors associated with a frightening visual experience.

DESIGN: Multicenter, prospective study.

METHODS: Sixty-five patients who had vitreous surgery under regional (retrobulbar or peribulbar) anesthesia in five centers in Ireland, Singapore, and Hong Kong were interviewed within 2 hours of their operation using a standardized questionnaire.

RESULTS: Thirty patients (46.2%) perceived light perception throughout the entire operation, 19 patients (29.2%) experienced transient loss of light perception, and 16 patients (24.6%) experienced no light perception throughout the entire duration of the surgery. Nine patients (13.8%) were frightened by their intraoperative visual experiences. Patients who were frightened by their visual experiences were more likely to see color (100%) than those who were not frightened (55.4%) (P = .010). The mean age of the patients who were frightened was lower (51.8 years) compared with those who were not frightened (64.6 years) (P = .003). The mean duration of surgery was longer for patients who were frightened (118.9 minutes) compared with those who were not frightened (91.2 minutes) (P = .047).

CONCLUSIONS: Most patients undergoing vitreous surgery under regional anesthesia retained at least light perception intraoperatively. Importantly, 13.8% of patients were frightened by their visual experiences. A younger age, longer duration of surgery, and perception of color were risk factors for a frightening visual experience.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app